JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 106 filers reported holding JOUNCE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 1.23 and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $1,686,000 | -17.9% | 248,347 | +1.0% | 0.70% | -16.1% |
Q4 2021 | $2,053,000 | +32.5% | 245,829 | +17.9% | 0.83% | -5.0% |
Q3 2021 | $1,550,000 | -9.0% | 208,559 | -16.8% | 0.88% | +15.3% |
Q2 2021 | $1,704,000 | -52.6% | 250,644 | -28.4% | 0.76% | -61.2% |
Q1 2021 | $3,595,000 | +26.3% | 350,000 | -13.9% | 1.96% | +18.6% |
Q4 2020 | $2,847,000 | – | 406,665 | – | 1.65% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
TRV GP II, LLC | 572,829 | $1,340,000 | 100.00% |
TRV GP III, LLC | 1,148,780 | $2,688,000 | 1.17% |
COWEN AND COMPANY, LLC | 3,647,430 | $8,535,000 | 0.82% |
Octagon Capital Advisors LP | 1,400,000 | $3,276,000 | 0.56% |
Deep Track Capital, LP | 4,259,653 | $9,968,000 | 0.46% |
PFM Health Sciences, LP | 4,094,488 | $9,581,000 | 0.35% |
RTW INVESTMENTS, LP | 5,106,341 | $11,949,000 | 0.28% |
Omega Fund Management, LLC | 275,513 | $645,000 | 0.24% |
Monarch Partners Asset Management LLC | 228,370 | $534,000 | 0.16% |
Orbimed Advisors | 2,928,900 | $6,854,000 | 0.13% |